Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer

International Journal of Oncology

Volumn 37, Issue 5, 2010, Pages 1219-1228

  Lo Nigro, Cristiana ^a   Monteverde, Martino ^a   Riba, Michela ^a   Lattanzio, Laura ^a   Tonissi, Federica ^a   Garrone, Ornella ^a   Heouaine, Abdelhamid ^a   Gallo, Fabio ^b   Ceppi, Marcello ^b   Borghi, Felice ^a   Comino, Alberto ^a   Merlano, Marco ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Chemotherapy; Expression profiling; Metastatic gastric cancer; Single nucleotide polymorphisms; Survival

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; CELL CYCLE REGULATION; CYP1A1 GENE; CYP3A4 GENE; DNA REPAIR; ERBB4 GENE; GADD45A GENE; GENE; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; MAPK1 GENE; METASTASIS; PRIORITY JOURNAL; PTEN GENE; STOMACH CANCER; TP63 GENE;

EID: 77957864335     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000773     Document Type: Article

References (30)

1. Devesa SS, Blot WJ and Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83: 2049-2053, 1998.
2. Wolschke C, Goekkurt E, A-Batran SE and Hossfeld DK: Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer - report of 2 cases. Onkologie 28: 589-592, 2005. (Pubitemid 41513145)
3. Ichikawa W: Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer 9: 145-155, 2006.
4. Fareed KR, Kaye P, Soomro IN, et al: Biomarkers of response to therapy in oesophago-gastric cancer. Gut 58: 127-143, 2009.
5. Tanabe L, Scherf U, Smith LH, Lee JK, Hunter L and Weinstein JN: MedMiner: an Internet text-mining tool for biomedical information, with application to gene expression profiling. Biotechniques 27: 1210-1214, 1216-1217, 1999.
6. Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 57: 289-300, 1995.
7. Janunger KG, Hafström L, Nygren P and Glimelius B: SBU-group: Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 40: 309-326, 2001.
8. Lee HS, Cho SB, Lee HE, et al: Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res 13: 4154-4163, 2007.
9. Marchet A, Mocellin S, Belluco C, et al: Gene expression profile of primary gastric cancer: towards the prediction of lymph node status. Ann Surg Oncol 14: 1058-1064, 2007.
10. Xu ZY, Chen JS and Shu YQ: Gene expression profile towards the prediction of patient survival of gastric cancer. Biomed Pharmacother 64: 133-139, 2010.
11. Napieralski R, Ott K, Kremer M, et al: Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 11: 3025-3031, 2005.
12. Wu WK, Sung JJ, Yu L, Li ZJ, Chu KM and Cho CH: Constitutive hypophosphorylation of extracellular signal-regulated kinases-1/2 and down-regulation of c-Jun in human gastric adenocarcinoma. Biochem Biophys Res Commun 373: 330-334, 2008.
13. Tamura G: Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 12: 192-198, 2006.
14. Bai Z, Ye Y, Chen D, et al: Homeoprotein Cdx2 and nuclear PTEN expression profiles are related to gastric cancer prognosis. APMIS 115: 1383-1390, 2007.
15. Zheng H, Takahashi H, Murai Y, et al: Low expression of FHIT and PTEN correlates with malignancy of gastric carcinomas: tissue-array findings. Appl Immunohistochem Mol Morphol 15: 432-440, 2007.
16. Tuna B, Unlu M, Aslan G, Secil M and Yorukoglu K: Diagnostic and prognostic impact of p63 immunoreactivity in renal malignancies. Anal Quant Cytol Histol 31: 118-122, 2009.
17. Urist MJ, Di Como CJ, Lu ML, et al: Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 161: 1199-1206, 2002.
18. Hallack Neto AE, Siqueira SA, Dulley FL, Ruiz MA, Chamone DA and Pereira J: p63 protein expression in high risk diffuse large B-cell lymphoma. J Clin Pathol 62: 77-79, 2009.
19. Hayashi M, Inokuchi M, Takagi Y, et al: High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 14: 7843-7849, 2008.
20. Su HI, Sammel MD, Velders L, et al: Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertil Steril (In press).
21. Aubele M, Auer G, Walch AK, et al: PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 96: 801-807, 2007.
22. Sassen A, Diermeier-Daucher S, Sieben M, et al: Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res 11: R50, 2009.
23. Rodríguez-Antona C, Leskelä S, Zajac M, et al: Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood 110: 3345-3351, 2007.
24. Kopp R, Rothbauer E, Ruge M, et al: Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 162: 115-132, 2003.
25. Han SW, Oh DY, Im SA, et al: Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100: 298-304, 2009.
26. Kim JG, Sohn SK, Chae YS, et al: TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol 64: 355-360, 2009.
27. Huang ZH, Hua D and Du X: Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol (In press).
28. Viguier J, Boige V, Miquel C, et al: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11: 6212-6217, 2005.
29. Okuda K, Sasaki H, Hikosaka Y, et al: Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res (In press).
30. Kalikaki A, Kanaki M, Vassalou H, et al: DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 10: 118-123, 2009.